The 36-month beta value for TRIB is at 1.18. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRIB is 10.96M, and currently, shorts hold a 0.91% of that float. The average trading volume for TRIB on October 14, 2024 was 1.30M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TRIB) stock’s latest price update
Trinity Biotech Plc ADR (NASDAQ: TRIB)’s stock price has gone rise by 10.50 in comparison to its previous close of 1.81, however, the company has experienced a 66.67% increase in its stock price over the last five trading days. zacks.com reported 2024-10-08 that TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
TRIB’s Market Performance
TRIB’s stock has risen by 66.67% in the past week, with a monthly rise of 22.70% and a quarterly drop of -34.64%. The volatility ratio for the week is 13.46% while the volatility levels for the last 30 days are 9.59% for Trinity Biotech Plc ADR The simple moving average for the past 20 days is 45.64% for TRIB’s stock, with a -6.66% simple moving average for the past 200 days.
Analysts’ Opinion of TRIB
ROTH Capital gave a rating of “Buy” to TRIB, setting the target price at $20 in the report published on July 29th of the previous year.
TRIB Trading at 7.12% from the 50-Day Moving Average
After a stumble in the market that brought TRIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.66% of loss for the given period.
Volatility was left at 9.59%, however, over the last 30 days, the volatility rate increased by 13.46%, as shares surge +25.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.70% lower at present.
During the last 5 trading sessions, TRIB rose by +66.67%, which changed the moving average for the period of 200-days by +3.63% in comparison to the 20-day moving average, which settled at $1.37. In addition, Trinity Biotech Plc ADR saw -6.76% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TRIB
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.32 for the gross margin
The net margin for Trinity Biotech Plc ADR stands at -0.38. The total capital return value is set at -0.19.
Based on Trinity Biotech Plc ADR (TRIB), the company’s capital structure generated 1.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.16. The debt to equity ratio resting at -2.83. The interest coverage ratio of the stock is -1.85.
Currently, EBITDA for the company is -13.48 million with net debt to EBITDA at -8.14. When we switch over and look at the enterprise to sales, we see a ratio of 1.87. The receivables turnover for the company is 3.31for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.
Conclusion
In conclusion, Trinity Biotech Plc ADR (TRIB) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
